Stock·NYSE·Healthcare
Thermo Fisher Scientific Inc. (TMO)
- Market cap
- $255.13B
- P/E
- 36.23
- Dividend yield
- 0.27%
- Street target
- $685.00median of 27 analysts
- 52-week range
- $435.27 $704.00
The short version
Where TMO stands today, in four lines, and what CleaRank Financial AI makes of it.
TMO at a glance
Thermo Fisher Scientific Inc. (TMO): Buy, 79/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($636.69 and $547.32).
- Earnings TMO beat estimates in 7 of its last 7 quarters, yet fell the next day after 5 of those beats.
- Insiders Insiders sold $172.4M and made no open-market purchases over the last 18 months.
- Valuation P/E of 36.2 against 31.9 for the Healthcare sector: broadly in line with peers (+14%).
Figures as of October 17, 2026.
CleaRank Financial AI
Thermo Fisher Scientific Inc. (TMO) carries a CleaRank rating of Buy and a model score of 79/100.
Trend is the strongest contributor: the price is 26.07% above its 200-day average and 8.37% above its 50-day average, and the 50-day average is 16.33% above the 200-day. Valuation weighs most against the score, with the P/S of 5.37 57.9% above the sector median. The 50-day average sits at $636.69 and the 200-day at $547.32, and the price rose 28.54% over the past year.
Only on CleaRank
Figures we compute ourselves from TMO's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $690.00 is 8.4% above the 50-day simple moving average of $636.69.Price above its 200-day average ›
The price is 26.1% above the 200-day simple moving average of $547.32.50-day average above the 200-day ›
The 50-day average ($636.69) is 16.3% above the 200-day average ($547.32), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 95% of its 52-week range, between $435.27 and $704.00.
TMO share price
Pick a period: each tab shows how far TMO has moved over it, to the last close.
Today's trading
Where TMO sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
3/5P/E below the sector median ›
The trailing P/E of 36.23 is 13.6% above the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 5.37 is 58.0% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $7.0B on revenue of $46.3B, a net margin of 15.0%.Beat estimates in most recent reports ›
TMO beat the EPS estimate in 7 of its last 7 reports.Pays a dividend ›
The trailing dividend yield is 0.27%, or $1.84 a share a year.
Key statistics
The headline figures for TMO.
As of October 17, 2026, TMO trades at $690.00, with a market value of $255.13B, a P/E ratio of 36.23 and a dividend yield of 0.27%.
What the numbers say
CleaRank Financial AI's reading of TMO's valuation, growth and risks.
Thermo Fisher Scientific Inc. (TMO) trades at 36.23 times trailing earnings, which is 13.6% above the Healthcare median of 31.9. The peer comparison on this page rates that P/E as broadly in line with peers. On sales, TMO trades at 5.37 times, a multiple 57.9% above the sector median of 3.4. The company has a market capitalisation of $255.1B and trailing earnings of $18.58 per share.
With revenue growth of 10.50%, TMO is 2.4 percentage points faster than the sector median of 8.1%. The business earns a net margin of 15.04% and an operating margin of 18.75% and a return on equity of 13.52%, above the sector median of 7.3%. The balance sheet and payout round out the picture, with debt-to-equity of 0.81 and a trailing dividend yield of 0.27% ($1.84 a share a year).
The July 23, 2026 report showed EPS of $6.03 against an estimate of $5.71, a beat of 5.60%. The share price nonetheless fell 0.71% in the first session after the report.
Across its last 7 reports, TMO beat the estimate every time, though the stock still fell in the first session after 5 of those 7 beats. Looking ahead, analysts expect EPS of $25.13 this fiscal year (growth of 9.9%) and $27.56 the year after (growth of 9.7%).
The 30-day standard deviation of TMO's daily returns is 1.69%.
TMO against the Healthcare sector
How TMO compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (14% difference), suggesting fair market pricing relative to industry standards.
Return vs XLV: Since May 6, 2025, TMO has gained 69.5% against a gain of 31.4% for XLV.
Performance against XLV
TMO and the Healthcare sector fund over the same days.
Revenue and earnings
How much TMO sells, and how much of it becomes profit.
Revenue growth: Revenue grew 3.9% in FY2025 to $44.6B, from $42.9B a year earlier.
Profit margin: The net margin was 15.1% in FY2025, up from 14.8% the year before.
Profitable: TMO earned $6.7B in FY2025.
Earnings reality check
Did TMO beat what analysts expected, and how did the stock react?
Earnings record: TMO beat the analyst estimate in 7 of the last 7 quarters.
Market reaction: The stock fell in the first session after 5 of those 7 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 23, 2026after close | $5.71 | $6.03 | +5.60% | -0.71% | +0.78% |
| Oct 22, 2025after close | $5.50 | $5.79 | +5.27% | +0.83% | -1.57% |
| Jul 23, 2025after close | $5.23 | $5.36 | +2.49% | +1.78% | +2.26% |
| Apr 23, 2025after close | $5.10 | $5.15 | +0.98% | -1.15% | -0.61% |
| Jan 30, 2025after close | $5.94 | $6.10 | +2.69% | -1.48% | -5.61% |
| Oct 23, 2024after close | $5.25 | $5.28 | +0.57% | -3.31% | -4.49% |
| Jul 24, 2024after close | $5.13 | $5.37 | +4.68% | -0.64% | +0.61% |
As of October 17, 2026, TMO has beaten the analyst EPS estimate in 7 of its last 7 reported quarters and fell in the first trading session after 5 of those beats; its latest report, on July 23, 2026, came in 5.60% above the estimate and the stock moved -0.71% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 64.0, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 64.0 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of TMO
The score, the reasoning behind it, and what could move the price next.
TMO is trending up. At $690.00, the stock sits 8.37% above its 50-day average of $636.69 and 26.07% above its 200-day average of $547.32. Near the top of its 52-week range, the price is 1.99% below the high of $704.00 and 58.52% above the low of $435.27. The 50-day average is 16.33% above the 200-day, a pattern that backs up the move instead of cutting against it.
The 14-day RSI of 64.0 is in the bullish zone, below the overbought line, and the MACD line is positive. The record is positive across every period shown: the price rose 29.58% over the past three months, rose 31.03% over the past six months and rose 28.54% over the past year.
Earnings beat ›
The July 23, 2026 report beat the EPS estimate by 5.60%, and the share price fell 0.71% in the first session after it.
Source: Earnings report, July 23, 2026Rating reaffirmed ›
Barclays kept its Overweight rating on October 7, 2026.
Source: Analyst action, Barclays, October 7, 2026
New analyst coverage ›
CLSA started coverage at Outperform on September 3, 2026.
Source: Analyst action, CLSA, September 3, 2026
- Two levels matter most: the 52-week high at $704.00, which sits above the price, and the 20-day EMA at $663.95, which sits below it.
- The 14-day RSI reads 64.0, in the bullish zone, with the MACD line positive; readings above 70 or below 30 mark stretched momentum.
- After the July 23, 2026 report the share price fell 0.71% in the first session; TMO beat estimates in 7 of the last 7 reports.
The uptrend rests on TMO staying above its 50-day average at $636.69 and its 200-day average at $547.32; a close below the 50-day would be the first crack in it. On a pullback, the first level the price would meet is the 20-day EMA at $663.95.
TMO has the 52-week high of $704.00 as the next level overhead. With the RSI in the bullish zone, momentum still supports the move.
Technical indicators
Momentum and trend for TMO, from its daily closes.
As of October 17, 2026, with TMO at $690.00, its 14-day RSI is 64.0 (showing bullish momentum without being overbought), its 50-day simple moving average is $636.69 and its 200-day is $547.32.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What TMO moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, TMO's 1-year correlation of daily returns is +0.41 with S&P 500 (SPY), +0.29 with Nasdaq 100 (QQQ), +0.15 with Bitcoin (BTC) and +0.04 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
23 of 27 analysts rate it a buy or strong buy, 3 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $685.00 is 0.7% below the price.More buy ratings than three months ago ›
23 of 27 rate it a buy now, against 22 of 28 three months ago.
TMO Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Maintains | Overweight |
| Sep 9, 2026 | UBS | Assumes | Buy |
| Sep 3, 2026 | CLSA | Initiates | Outperform |
| Jul 27, 2026 | Piper Sandler | Maintains | Neutral |
| Jul 27, 2026 | Morgan Stanley | Maintains | Overweight |
| Jul 24, 2026 | RBC Capital | Maintains | Sector Perform |
As of October 17, 2026, 27 Wall Street analysts cover TMO: 23 rate it a buy or strong buy, 3 a hold and 1 a sell or strong sell. Their 12-month price targets range from $560.00 to $800.00, with a median of $685.00, 0.7% below the price of $690.00.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
TMO trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from TMO's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much TMO tends to move, against the market and on its own.
The long record
TMO's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
4/4Average daily move under 2% ›
The price has moved 1.69% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 39.6%, from December 2021 to May 2025, regained by September 2026.Most 1-year holds ended higher ›
76% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $47,075, against $42,055 in the S&P 500 (SPY).
TMO Drawdowns & Recovery
As of October 17, 2026, TMO's worst peak-to-trough fall over the last 10 years with dividends reinvested was -39.6% (December 2021 to May 2025); it regained that peak by September 2026, 16 months after the low, and 76% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into TMO in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: TMO beat the S&P 500 over this period: $47,075 against $42,055.
A $10,000 investment in TMO in October 2016 would be worth about $47,075 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to TMO, and which have not.
Strongest month, July: an average of +8.70%, up in 8 of 10 years.
Weakest month, February: an average of -4.52%, up in 3 of 10 years.
This month, October: has averaged +0.53%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, TMO's strongest calendar month has been July (average +8.70%, up in 8 of 10 years) and its weakest February (average -4.52%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in TMO, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in TMO today could grow to about $24,925 by 2036 in the base case, with a 90th-percentile outcome near $73,388 and a 10th-percentile outcome around $8,465. The simulation models price only; at today's 0.27% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
TMO Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $994 for TMO by 2030 in the base case, from $690 today (1.4x over 4 years). The 10th-percentile path ends near $502. These are outcomes of a Monte Carlo simulation run on TMO's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $537 | $756 | $1,064 | |
| 2028 | $511 | $828 | $1,342 | |
| 2029 | $502 | $907 | $1,640 | |
| 2030 | $502 | $994 | $1,968 | |
| 2031 | $508 | $1,089 | $2,338 |
Method: a lognormal simulation of TMO's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
TMO insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought TMO shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 17, 2026, TMO insiders reported 34 open-market sales worth $172.4M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2026 | Gianluca Pettiti
President
|
Sell | 4.1K | $2.5M |
| Aug 31, 2026 | Gianluca Pettiti
President
|
Option | 3.7K | $1.2M |
| Aug 24, 2026 | Marc N Casper
Chief Executive Officer
|
Sell | 275 | $172.4K |
| Aug 24, 2026 | Marc N Casper
Chief Executive Officer
|
Option | 275 | $85.1K |
| Aug 21, 2026 | Marc N Casper
Chief Executive Officer
|
Sell | 20.0K | $12.6M |
| Aug 21, 2026 | Marc N Casper
Chief Executive Officer
|
Option | 20.0K | $6.2M |
| Aug 19, 2026 | Lisa P Britt
Officer
|
Sell | 11.4K | $7.0M |
| Aug 19, 2026 | Lisa P Britt
Officer
|
Option | 11.4K | $4.8M |
| Aug 11, 2026 | Michael D Shafer
Officer
|
Sell | 25.5K | $15.3M |
| Aug 11, 2026 | Michael D Shafer
Officer
|
Option | 25.5K | $9.4M |
| Aug 7, 2026 | Marc N Casper
Chief Executive Officer
|
Sell | 4.9K | $2.9M |
| Aug 7, 2026 | Joseph R. Holmes
Officer
|
Sell | 420 | $245.6K |
| Aug 7, 2026 | Marc N Casper
Chief Executive Officer
|
Option | 275 | $85.1K |
| Aug 7, 2026 | Joseph R. Holmes
Officer
|
Option | 420 | $130.0K |
| Aug 6, 2026 | Marc N Casper
Chief Executive Officer
|
Sell | 15.0K | $8.6M |
| Aug 6, 2026 | Lisa P Britt
Officer
|
Sell | 5.9K | $3.4M |
| Aug 6, 2026 | Lisa P Britt
Officer
|
Option | 5.9K | $1.8M |
| Aug 6, 2026 | Marc N Casper
Chief Executive Officer
|
Option | 10.0K | $3.1M |
| Aug 5, 2026 | Marc N Casper
Chief Executive Officer
|
Sell | 15.0K | $8.6M |
| Aug 5, 2026 | Marc N Casper
Chief Executive Officer
|
Option | 10.0K | $3.1M |
| Jul 27, 2026 | Gianluca Pettiti
President
|
Sell | 400 | $226.0K |
| May 20, 2026 | Nelson J Chai
Director
|
Grant | 499 | - |
| May 20, 2026 | Ruby R Chandy
Director
|
Grant | 499 | - |
| May 20, 2026 | C. Martin M.d. Harris
Director
|
Grant | 499 | - |
| May 20, 2026 | Tyler Jacks
Director
|
Grant | 499 | - |
| May 20, 2026 | Jennifer M Johnson
Director
|
Grant | 499 | - |
| May 20, 2026 | R Alexandra Keith
Director
|
Grant | 499 | - |
| May 20, 2026 | Karen S. Lynch
Director
|
Grant | 499 | - |
| May 20, 2026 | Debora L Spar
Director
|
Grant | 499 | - |
| May 20, 2026 | Scott M Sperling
Director
|
Grant | 499 | - |
| May 20, 2026 | Dion J Weisler
Director
|
Grant | 499 | - |
| Apr 27, 2026 | Gianluca Pettiti
President
|
Sell | 400 | $185.1K |
| Mar 11, 2026 | Michael D Shafer
Officer
|
Sell | 1.6K | $802.5K |
| Mar 5, 2026 | Marc N Casper
Chief Executive Officer
|
Sell | 4.0K | $2.1M |
| Mar 5, 2026 | Marc N Casper
Chief Executive Officer
|
Option | 4.0K | $1.2M |
| Mar 4, 2026 | Marc N Casper
Chief Executive Officer
|
Sell | 10.0K | $5.1M |
| Mar 4, 2026 | Marc N Casper
Chief Executive Officer
|
Option | 10.0K | $3.1M |
| Feb 25, 2026 | Lisa P Britt
Officer
|
Grant | 2.0K | - |
| Feb 25, 2026 | Marc N Casper
Chief Executive Officer
|
Grant | 14.8K | - |
| Feb 25, 2026 | Joseph R. Holmes
Officer
|
Grant | 770 | - |
| Feb 25, 2026 | Michel Lagarde
Chief Operating Officer
|
Grant | 2.2K | - |
| Feb 25, 2026 | Frederick M. Lowery
Officer
|
Grant | 1.6K | - |
| Feb 25, 2026 | Gianluca Pettiti
Officer
|
Grant | 5.8K | - |
| Feb 25, 2026 | Michael D Shafer
Officer
|
Grant | 4.7K | - |
| Feb 25, 2026 | Thomas B Shropshire Jr.
General Counsel
|
Grant | 978 | - |
| Feb 25, 2026 | Stephen Williamson
Chief Financial Officer
|
Grant | 1.5K | - |
| Feb 9, 2026 | Gianluca Pettiti
Officer
|
Sell | 400 | $216.5K |
| Dec 10, 2025 | Scott M Sperling
Director
|
Grant | 4.4K | - |
| Dec 4, 2025 | Michel Lagarde
Chief Operating Officer
|
Sell | 22.0K | $12.4M |
| Dec 4, 2025 | Michel Lagarde
Chief Operating Officer
|
Option | 40.7K | $4.9M |
| Dec 3, 2025 | Michel Lagarde
Chief Operating Officer
|
Sell | 62.0K | $36.1M |
| Dec 3, 2025 | Michel Lagarde
Chief Operating Officer
|
Option | 104.0K | $10.9M |
| Dec 2, 2025 | Frederick M. Lowery
Officer
|
Sell | 13.8K | $8.2M |
| Dec 2, 2025 | Frederick M. Lowery
Officer
|
Option | 13.8K | $3.5M |
| Nov 25, 2025 | Michael D Shafer
Officer
|
Sell | 10.7K | $6.4M |
| Nov 25, 2025 | Michael D Shafer
Officer
|
Option | 10.7K | $2.8M |
| Nov 14, 2025 | Stephen Williamson
Chief Financial Officer
|
Grant | 433 | - |
| Nov 13, 2025 | Michel Lagarde
Chief Operating Officer
|
Sell | 4.6K | $2.8M |
| Nov 13, 2025 | Michel Lagarde
Chief Operating Officer
|
Option | 4.6K | $1.2M |
| Nov 12, 2025 | Lisa P Britt
Officer
|
Sell | 1.1K | $622.1K |
| Nov 10, 2025 | Gianluca Pettiti
Officer
|
Sell | 3.0K | $1.7M |
| Nov 10, 2025 | Gianluca Pettiti
Officer
|
Option | 3.0K | $845.7K |
| Nov 7, 2025 | Lisa P Britt
Officer
|
Sell | 10.2K | $5.8M |
| Nov 7, 2025 | Lisa P Britt
Officer
|
Option | 8.5K | $2.2M |
| Oct 27, 2025 | Marc N Casper
Chief Executive Officer
|
Sell | 24.4K | $13.9M |
| Oct 27, 2025 | Marc N Casper
Chief Executive Officer
|
Option | 24.4K | $6.2M |
| Oct 24, 2025 | Gianluca Pettiti
Officer
|
Sell | 400 | $229.7K |
| Sep 5, 2025 | Marc N Casper
Chief Executive Officer
|
Sell | 400 | $200.2K |
| Sep 5, 2025 | Marc N Casper
Chief Executive Officer
|
Option | 400 | $101.6K |
| Aug 29, 2025 | Joseph R. Holmes
Officer
|
Sell | 385 | $189.7K |
| Aug 29, 2025 | Joseph R. Holmes
Officer
|
Option | 385 | $97.8K |
| Aug 22, 2025 | Marc N Casper
Chief Executive Officer
|
Sell | 10.0K | $5.0M |
| Aug 22, 2025 | Marc N Casper
Chief Executive Officer
|
Option | 10.0K | $2.5M |
| Aug 20, 2025 | Marc N Casper
Chief Executive Officer
|
Sell | 496 | $248.0K |
| Aug 20, 2025 | Marc N Casper
Chief Executive Officer
|
Option | 496 | $126.0K |
| Aug 7, 2025 | Marc N Casper
Chief Executive Officer
|
Sell | 18.0K | $8.2M |
| Aug 7, 2025 | Marc N Casper
Chief Executive Officer
|
Option | 18.0K | $4.6M |
| Jul 25, 2025 | Gianluca Pettiti
Officer
|
Sell | 400 | $192.0K |
| Jun 2, 2025 | Thomas B Shropshire Jr.
General Counsel
|
Grant | 5.4K | - |
| May 21, 2025 | Nelson J Chai
Director
|
Grant | 565 | - |
| May 21, 2025 | Ruby R Chandy
Director
|
Grant | 565 | - |
| May 21, 2025 | C. Martin M.d. Harris
Director
|
Grant | 565 | - |
| May 21, 2025 | Tyler Jacks
Director
|
Grant | 565 | - |
| May 21, 2025 | Jennifer M Johnson
Director
|
Grant | 565 | - |
| May 21, 2025 | R Alexandra Keith
Director
|
Grant | 565 | - |
| May 21, 2025 | Karen S. Lynch
Director
|
Grant | 565 | - |
| May 21, 2025 | James Charles Mullen
Director
|
Grant | 565 | - |
| May 21, 2025 | Debora L Spar
Director
|
Grant | 565 | - |
| May 21, 2025 | Scott M Sperling
Director
|
Grant | 565 | - |
| May 21, 2025 | Dion J Weisler
Director
|
Grant | 565 | - |
| May 12, 2025 | Gianluca Pettiti
Officer
|
Sell | 400 | $164.4K |
| Apr 28, 2025 | Gianluca Pettiti
Officer
|
Sell | 300 | $129.0K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.